Results 221 to 230 of about 392,253 (296)

Tissue-Free Circulating Tumor DNA Assay and Patient Outcome in a Phase III Trial of FOLFOX-Based Adjuvant Chemotherapy (Alliance N0147). [PDF]

J Clin Oncol
Sinicrope FA, Segovia D, Sharma N, Alberts SR, Hardin A, Rich T, Shi Q.   +6 more
europepmc   +1 more source

Optimal Indication of D3 Lymph Node Dissection for Non‐Metastatic Colon Cancers by Tumor Stages: Evaluation of Therapeutic Value Index for Each Lymph Node Station

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aims To explore the therapeutic impact of D3 lymph node dissection for non‐metastatic colon cancers, evaluating the therapeutic value index for each lymph node station according to surgical stages. Methods Consecutive patients with surgical Stage I–III colon and rectosigmoid cancer who underwent curative resection between January 2003 and ...
Akira Ouchi, Kozo Kataoka, Eiji Shinto, Takashi Akiyoshi, Takefumi Yoshida, Yasuyuki Takamizawa, Yukihide Kanemitsu, Hirotoshi Kobayashi, Hideki Ueno, on behalf of the Lymph Nodes Committee of JSCCR   +9 more
wiley   +1 more source

Impact of neoadjuvant and adjuvant chemotherapy on breast cancer prognosis in a propensity score matched population. [PDF]

Sci Rep
Xu Y, Liu B, Chen C, Mao F, Shen S, Zhang X, Huang X, Lin Y, Zhou Y, Sun Q.   +9 more
europepmc   +1 more source

Potential Survival Benefit of Neoadjuvant Docetaxel, Cisplatin and 5‐Fluorouracil Therapy in Patients With Esophageal Squamous Cell Carcinoma With Multiple Lymph Node Metastases: A Single‐Institute Propensity Score Analysis

Annals of Gastroenterological Surgery, EarlyView.
Although neoadjuvant chemotherapy with fluorouracil, cisplatin, and docetaxel (NAC‐DCF) is the current standard neoadjuvant regimen for esophageal squamous cell carcinoma, its substantial toxicity underscores the need to identify patients who derive the greatest benefit.
Eiji Higaki, Tetsuya Abe, Hironori Fujieda, Shigenori Kadowaki, Tsutomu Tanaka, Masahiro Tajika, Koji Komori, Seiji Ito, Isao Oze, Kei Muro   +9 more
wiley   +1 more source

Adjuvant chemotherapy appears less effective in undernourished lung cancer patients as assessed by the controlling nutritional status score: a retrospective cohort study. [PDF]

J Thorac Dis
Onodera K, Notsuda H, Kumata S, Watanabe T, Watanabe Y, Suzuki T, Hirama T, Oishi H, Okada Y.   +8 more
europepmc   +1 more source

Sex‐Based Body Composition Changes in Patients With Rectal Cancer Undergoing Preoperative Chemoradiotherapy: A Prospective Observational Study

Annals of Gastroenterological Surgery, EarlyView.
This prospective study observed that preoperative chemoradiotherapy for rectal cancer was associated with reductions in body fat and grip strength, which appeared to be more pronounced in female patients. These findings suggest that sex‐sensitive nutritional and exercise support may be beneficial to help maintain muscle mass and physical function ...
Shinya Abe, Hiroaki Nozawa, Kentaro Abe, Yumi Yokota, Shunsuke Hori, Yusuke Taguchi, Mitsutaka Yakabe, Kazuhito Sasaki, Sumito Ogawa, Soichiro Ishihara   +9 more
wiley   +1 more source

Association between adjuvant chemotherapy and risk of incisional hernia after colorectal cancer resection - a single-centre cohort study. [PDF]

Langenbecks Arch Surg
Rasmussen MC, Baastrup NN, Gundestrup AK, Kanstrup CTB, Kleif J, Bertelsen CA.   +5 more
europepmc   +1 more source

Clinical utility of pharyngeal high‐resolution manometry with impedance for upper esophageal sphincter dysfunction in gastroenterology

Advances in Digestive Medicine, EarlyView.
Abstract Pharyngeal high‐resolution manometry with impedance (P‐HRM‐I) is an established assessment method used to evaluate pharyngeal swallowing. It provides precise quantification of swallowing biomechanics that enable the detection of alterations in swallowing physiology.
Mistyka Schar, Taher Omari, Michal Szczesniak, Chien‐Lin Chen, Richard Heddle, Charles Cock   +5 more
wiley   +1 more source

Value of adjuvant chemotherapy in IB-lIA cervical adenocarcinoma: A multicenter retrospective study. [PDF]

Chin Med J (Engl)
Wu Y, Ao M, Zhang H, Wang K, Fang M, Lyu X, Chen G, Lyu T, Li B.   +8 more
europepmc   +1 more source

Safety and Effectiveness of Sutimlimab in Cold Agglutinin Disease: A Real‐World International Experience

American Journal of Hematology, EarlyView.
ABSTRACT Sutimlimab is a monoclonal antibody against complement fraction C1s approved for the treatment of hemolytic anemia due to cold agglutinin disease (CAD). Here, we analyzed and report the largest international CAD cohort of sutimlimab‐treated patients ever reported to highlight its safety and effectiveness in the real‐world setting. We accrued a
Bruno Fattizzo, Elisa Sambruna, Yoshitaka Miyakawa, Marc Michel, Carlo Visco, Michael Fillitz, George Kannourakis, Maria Bruna Greve, Moritz Kleemiss, Johan Cid, Andrea Patriarca, Laura Pavan, Arbana Dizdari, Nilla Maschio, Antonella Sau, Cinzia Bitetti, Riccardo Mario Colombo, Luigi Curreli, Dorela Lame, Uros Markovic, Fabrizio Pappagallo, Giacinto Luca Pedone, Davide Rapezzi, Vincenzo Sammartano, Nicola Tumedei, Antonio Giovanni Solimando, Jalink Marit, Luana Fianchi, Jahanzaib Khwaja, Antonio De Vivo, Francesco Lanza, Fabrizio Vianello, Esther N. Oliva, Catherine Broome, Francesco Passamonti, Ulrich Jaeger, Bernd Jilma, Guillaume Moulis, Wilma Barcellini   +38 more
wiley   +1 more source